Agreement between parents' and clinical researchers' ratings of behavioral problems in children with fragile X syndrome and chromosome 15 imprinting disorders.

[1]  A. Mannion,et al.  Relationships between challenging behavior and gastrointestinal symptoms, sleep problems, and internalizing and externalizing symptoms in children and adolescents with Angelman syndrome. , 2022, Research in developmental disabilities.

[2]  R. Hagerman,et al.  Fragile X Syndrome: From Molecular Aspect to Clinical Treatment , 2022, International journal of molecular sciences.

[3]  L. Servais,et al.  Therapies in preclinical and clinical development for Angelman syndrome , 2021, Expert opinion on investigational drugs.

[4]  Jane E. Roberts,et al.  Fragile X syndrome: an overview of cause, characteristics, assessment and management , 2020, Paediatrics and Child Health.

[5]  W. Kaufmann,et al.  Response to Placebo in Fragile X Syndrome Clinical Trials: An Initial Analysis , 2020, Brain sciences.

[6]  H. Andrews,et al.  Factor Structure of the Aberrant Behavior Checklist in Individuals with Fragile X Syndrome: Clarifications and Future Guidance. , 2020, Journal of child and adolescent psychopharmacology.

[7]  S. A. Vera,et al.  Intellectual functioning and behavioural features associated with mosaicism in fragile X syndrome , 2019, Journal of Neurodevelopmental Disorders.

[8]  L. Fusar-Poli,et al.  What are we targeting when we treat autism spectrum disorder? A systematic review of 406 clinical trials , 2019, Autism : the international journal of research and practice.

[9]  G. Capone,et al.  Comparison of Aberrant Behavior Checklist profiles across Prader–Willi syndrome, Down syndrome, and autism spectrum disorder , 2018, American journal of medical genetics. Part A.

[10]  L. Lach,et al.  Family impact of childhood neurodevelopmental disability: considering adaptive and maladaptive behaviour , 2018, Journal of intellectual disability research : JIDR.

[11]  D. Amor,et al.  Exploring autism symptoms in an Australian cohort of patients with Prader-Willi and Angelman syndromes , 2018, Journal of Neurodevelopmental Disorders.

[12]  P. McGill,et al.  How common are challenging behaviours amongst individuals with Fragile X Syndrome? A systematic review. , 2018, Research in developmental disabilities.

[13]  C. Dissanayake,et al.  Intragenic DNA methylation in buccal epithelial cells and intellectual functioning in a paediatric cohort of males with fragile X , 2018, Scientific Reports.

[14]  S. Einfeld,et al.  A review of clinical trials of oxytocin in Prader–Willi syndrome , 2017, Current opinion in psychiatry.

[15]  A. Garland,et al.  Psychiatric comorbidity in autism spectrum disorder: Correspondence between mental health clinician report and structured parent interview , 2017, Autism : the international journal of research and practice.

[16]  Heather Cody Hazlett,et al.  Fragile X syndrome , 2017, Nature Reviews Disease Primers.

[17]  J. Sweeney,et al.  Challenges in Conducting Clinical Trials for Pharmacotherapies in Fragile X Syndrome: Lessons Learned , 2017, Pharmaceutical Medicine.

[18]  A. Reiss,et al.  Updated report on tools to measure outcomes of clinical trials in fragile X syndrome , 2017, Journal of Neurodevelopmental Disorders.

[19]  J. Sweeney,et al.  Fragile X targeted pharmacotherapy: lessons learned and future directions , 2017, Journal of Neurodevelopmental Disorders.

[20]  M. Bear,et al.  Arbaclofen in fragile X syndrome: results of phase 3 trials , 2017, Journal of Neurodevelopmental Disorders.

[21]  D. Budimirovic,et al.  Fragile X Syndrome: Lessons Learned from the Most Translated Neurodevelopmental Disorder in Clinical Trials , 2017, Translational neuroscience.

[22]  Z. Tümer,et al.  Recent Advances in Imprinting Disorders , 2017, Clinical genetics.

[23]  Sven Bölte,et al.  The objectivity of the Autism Diagnostic Observation Schedule (ADOS) in naturalistic clinical settings , 2016, European Child & Adolescent Psychiatry.

[24]  H. Stefánsson,et al.  Parental Origin of Interstitial Duplications at 15q11.2-q13.3 in Schizophrenia and Neurodevelopmental Disorders , 2016, PLoS genetics.

[25]  D. Bailey,et al.  Aggression in fragile X syndrome. , 2016, Journal of intellectual disability research : JIDR.

[26]  Sébastien Jacquemont,et al.  Mavoglurant in fragile X syndrome: Results of two randomized, double-blind, placebo-controlled trials , 2016, Science Translational Medicine.

[27]  L. Vissers,et al.  Genetic studies in intellectual disability and related disorders , 2015, Nature Reviews Genetics.

[28]  A. Guastella,et al.  Predictors of placebo response in pharmacological and dietary supplement treatment trials in pediatric autism spectrum disorder: a meta-analysis , 2015, Translational Psychiatry.

[29]  Mo Wang,et al.  The validity of the multi-informant approach to assessing child and adolescent mental health. , 2015, Psychological bulletin.

[30]  Stormy J. Chamberlain,et al.  Prader-Willi, Angelman, and 15q11-q13 Duplication Syndromes. , 2015, Pediatric clinics of North America.

[31]  S. Spence,et al.  A survey of seizures and current treatments in 15q duplication syndrome , 2014, Epilepsia.

[32]  Jennifer L. Hammond,et al.  An analysis of the topography, severity, potential sources of reinforcement, and treatments utilized for skin picking in Prader-Willi syndrome. , 2013, Research in developmental disabilities.

[33]  Tiina K. Urv,et al.  Outcome Measures for Clinical Trials in Fragile X Syndrome , 2013, Journal of developmental and behavioral pediatrics : JDBP.

[34]  Jonathan D. Schmidt,et al.  An evaluation of the Aberrant Behavior Checklist for children under age 5. , 2013, Research in developmental disabilities.

[35]  E. Thiele,et al.  Neurologic manifestations of Angelman syndrome. , 2013, Pediatric neurology.

[36]  Allan L. Reiss,et al.  Psychometric Study of the Aberrant Behavior Checklist in Fragile X Syndrome and Implications for Targeted Treatment , 2012, Journal of autism and developmental disorders.

[37]  Whitney Guthrie,et al.  Convergent validity of the Mullen Scales of Early Learning and the differential ability scales in children with autism spectrum disorders. , 2011, American journal on intellectual and developmental disabilities.

[38]  Psychologie.  Wechsler Preschool and Primary Scale of Intelligence , 2011, Definitions.

[39]  Daniel J Driscoll,et al.  Clinical and genetic aspects of Angelman syndrome , 2010, Genetics in Medicine.

[40]  S. Targum,et al.  The clinical global impressions scale: applying a research tool in clinical practice. , 2007, Psychiatry (Edgmont (Pa. : Township)).

[41]  S. Sparrow,et al.  Adaptive functioning and behaviour problems in relation to level of education in children and adolescents with intellectual disability. , 2005, Journal of intellectual disability research : JIDR.

[42]  A. Kazdin,et al.  Informant discrepancies in the assessment of childhood psychopathology: a critical review, theoretical framework, and recommendations for further study. , 2005, Psychological bulletin.

[43]  D. J. Driscoll,et al.  Prader-Willi syndrome. , 1984, Current problems in pediatrics.

[44]  J. R. Landis,et al.  The measurement of observer agreement for categorical data. , 1977, Biometrics.

[45]  C. Lord,et al.  Restricted and Repetitive Behaviors in Young Children with Autism Spectrum Disorders , 2007, Journal of autism and developmental disorders.